HOLLY SPRINGS — Genentech is increasing its bet on Holly Springs, announcing it will more than double the investment behind its planned manufacturing facility in southern Wake County.
The biotechnology company, known for drugs used to treat cancer and rare diseases, said last week it is raising the project’s total investment to $2 billion and expanding its hiring plans to 500 jobs. The move builds on the company’s initial commitment last year to invest $700 million and create roughly 400 positions.
For Holly Springs and the Triangle’s life sciences economy, the announcement is another sign that the region’s manufacturing footprint is still expanding — even as some parts of the biotech sector deal with tighter budgets, shifting priorities and layoffs elsewhere in the industry.
The Holly Springs facility will be Genentech’s first site on the East Coast. The company is based in South San Francisco and operates as a subsidiary of Swiss pharmaceutical giant Roche.
Construction began last fall, and the company’s goal is to have the site fully operational by 2029. The plant is expected to manufacture pharmaceutical products, including a weight loss drug, positioning the facility to serve one of the fastest-growing segments in health care.
The larger investment also strengthens Holly Springs’ emergence as a biotech manufacturing hub, joining a cluster that includes Amgen, Fujifilm Diosynth, CSL Seqirus and Janssen Pharmaceuticals. Those companies have helped reshape southern Wake County into a major destination for large-scale pharmaceutical production, supported by workforce development programs, infrastructure upgrades and proximity to research institutions across the Triangle.
Genentech’s expansion is also part of a broader trend: Drugmakers increasingly want production closer to U.S. markets, both to reduce supply-chain risk and to speed up manufacturing timelines for high-demand therapies. Large capital projects like the Holly Springs facility can take years to plan, permit and build, making the decision to scale up investment early in the process a significant signal about long-term demand expectations.
The weight loss drug pipeline has been a particularly strong driver for manufacturing jobs across North Carolina. New generations of GLP-1 and related therapies have shifted from niche treatments into mainstream demand, creating pressure for more capacity — not just in research and development, but in production, packaging and distribution.
In the Triangle, Novo Nordisk and Eli Lilly already employ thousands of workers in manufacturing roles tied to weight loss drugs, with multiple facilities producing active ingredients and finished products. Genentech’s Holly Springs project adds another major player to that supply chain.
